title: Overexpression of multiple myeloma SET domain (MMSET) is associated with advanced tumor aggressiveness and poor prognosis in serous ovarian carcinoma.
abstract: Multiple myeloma SET domain (MMSET) has been shown to be overexpressed in many different cancer tissues. Our study was to investigate the expression of MMSET in serous ovarian carcinoma and to evaluate its clinical significance in patients with serous ovarian carcinoma. Immunohistochemistry was performed to determine the expression of MMSET in 132 serous ovarian carcinoma, 32 normal ovarian and fallopian tube specimens. The high expression of MMSET was observed in 49.2% (65/132) in patients with serous ovarian carcinoma. MMSET high expression correlated with the advanced extent of serous ovarian carcinoma and poor outcome. MMSET may serve as a new molecular marker to predict the prognosis of serous ovarian carcinoma in the clinic.
authors.affiliation: Department of Gynecology, The Affiliated Tumor Hospital of Harbin Medical University, Harbin, China.
authors.forename: Shanshan
authors.initials: S
authors.lastname: Yang
authors.forename: Yunyan
authors.initials: Y
authors.lastname: Zhang
authors.forename: Fanling
authors.initials: F
authors.lastname: Meng
authors.forename: Yunduo
authors.initials: Y
authors.lastname: Liu
authors.forename: Bairong
authors.initials: B
authors.lastname: Xia
authors.forename: Min
authors.initials: M
authors.lastname: Xiao
authors.forename: Ye
authors.initials: Y
authors.lastname: Xu
authors.forename: Xiaoming
authors.initials: X
authors.lastname: Ning
authors.forename: Huiming
authors.initials: H
authors.lastname: Li
authors.forename: Ge
authors.initials: G
authors.lastname: Lou
mesh_terms: D000368:Aged; D014408:Biomarkers, Tumor / Q000235:genetics* / Q000378:metabolism; D018284:Cystadenocarcinoma, Serous / Q000175:diagnosis / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D005260:Female; D015870:Gene Expression; D011495:Histone-Lysine N-Methyltransferase / Q000235:genetics* / Q000378:metabolism; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000175:diagnosis / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D010053:Ovary / Q000378:metabolism / Q000473:pathology; D011379:Prognosis; D012097:Repressor Proteins / Q000235:genetics* / Q000378:metabolism; D016019:Survival Analysis
chemical_list: D014408:Biomarkers, Tumor; D012097:Repressor Proteins; D011495:Histone-Lysine N-Methyltransferase; C419586:NSD2 protein, human